HOME >> BIOLOGY >> NEWS
Findings Challenge Notion Of Withholding Food To Fight Rotavirus

CHAMPAIGN, Ill. -- Malnutrition slows recovery from rotaviral infection, scientists say. Their new research, which challenges the long-accepted approach of withholding food to rest the bowels of infants and animals infected with the virus, documents what happens during recovery.

As part of a series of experiments, a team of University of Illinois nutritionists, animal scientists and veterinary pathobiologists compared the activity of the intestine of healthy neonatal pigs with those that were infected with rotavirus and fed either normally or subjected to protein-energy malnutrition. With diminished nourishment, rotavirus appeared to be recognized by T-cells sent by the immune system, but the task of intestinal epithelial cell recovery was slowed dramatically.

Malnourished pigs still had diarrhea 16 days after infection, while nourished piglets recovered in nine days. Using cellular and molecular techniques, researchers watched the epithelial cells, which absorb nutrients when healthy, as they became infected and began producing rotavirus. They also monitored the progress of T-cells and other immune responses.

Rotavirus strikes virtually every child before the age of four, usually in the first two years of life, and ultimately kills an estimated 870,000 children annually worldwide. There is no cure, although a vaccine became available late last year.

"Our data show that an animal responds to nourishment -- that it can still absorb and clear the infection even during the period of diarrhea," said H. Rex Gaskins, a professor of animal sciences and veterinary pathobiology and a researcher in the U. of I. Division of Nutritional Sciences. "If food is withheld, that is malnutrition. This work eventually will allow us to define what macronutrients, such as protein, carbohydrate or fat, are important for intestinal recovery from enteric infections."

The study, published in the April issue of the Journal of Nutrition, indicates that malnutrition affe
'"/>

Contact: Jim Barlow, Life Sciences Editor
b-james3@uiuc.edu
217-333-5802
University of Illinois at Urbana-Champaign
31-Mar-1999


Page: 1 2

Related biology news :

1. Findings suggest need for new view of p53 cancer proteins interaction with DNA
2. Findings redefine mechanism of action of RNA helicase enzymes
3. Findings of novel nanoproperties in selenium produced by bacteria open new area of exploration
4. Findings could aid efforts to harness nature for making drugs
5. Findings offer clue to how molecule can both stimulate, suppress cell growth
6. Findings offer further understanding about growth and development in young male gymnasts
7. Findings in frog oocytes may help study of chromosome physiology
8. Findings aid understanding of neurodegenerative diseases
9. Findings show exceptional longevity runs in families
10. Findings give insight into how colon cells transform into precancerous polyps
11. Findings conclude sustained caffeine intake negates the benefits of creatine supplements

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Findings Challenge Notion Withholding Food Fight Rotavirus

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: